ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Age Related Macular Degeneration Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
Published Date: September 2025
|
Report Code: QYRE-Auto-8B9447
Home | Market Reports | People & Society
Global Age Related Macular Degeneration Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Age Related Macular Degeneration Drug- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031

Code: QYRE-Auto-8B9447
Report
September 2025
Pages:87
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma

Age Related Macular Degeneration Drug- Market Size

The global market for Age Related Macular Degeneration Drug was estimated to be worth US$ 8657 million in 2024 and is forecast to a readjusted size of US$ 12860 million by 2031 with a CAGR of 5.9% during the forecast period 2025-2031.

Age Related Macular Degeneration Drug- Market

Age Related Macular Degeneration Drug- Market

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.
North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.
The key players are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. Top 3 companies occupied about 79% market share.
This report aims to provide a comprehensive presentation of the global market for Age Related Macular Degeneration Drug, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Age Related Macular Degeneration Drug by region & country, by Type, and by Application.
The Age Related Macular Degeneration Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age Related Macular Degeneration Drug.
Market Segmentation

Scope of Age Related Macular Degeneration Drug- Market Report

Report Metric Details
Report Name Age Related Macular Degeneration Drug- Market
Forecasted market size in 2031 US$ 12860 million
CAGR 5.9%
Forecasted years 2025 - 2031
Segment by Type
  • Lucentis
  • Eylea
  • Avastin
  • Others
Segment by Application
  • Hospitals
  • Clinics
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Age Related Macular Degeneration Drug in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Age Related Macular Degeneration Drug- Market size in 2031?

Ans: The Age Related Macular Degeneration Drug- Market size in 2031 will be US$ 12860 million.

What is the Age Related Macular Degeneration Drug- Market share by region?

Ans: North America is the largest Age Related Macular Degeneration Drug market with about 65% market share. Europe is follower, accounting for about 29% market share.

What is the market share of major companies in Age Related Macular Degeneration Drug- Market?

Ans: Top 3 companies occupied about 79% market share.

Who are the main players in the Age Related Macular Degeneration Drug- Market report?

Ans: The main players in the Age Related Macular Degeneration Drug- Market are Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma

What are the Application segmentation covered in the Age Related Macular Degeneration Drug- Market report?

Ans: The Applications covered in the Age Related Macular Degeneration Drug- Market report are Hospitals, Clinics, Others

What are the Type segmentation covered in the Age Related Macular Degeneration Drug- Market report?

Ans: The Types covered in the Age Related Macular Degeneration Drug- Market report are Lucentis, Eylea, Avastin, Others

1 Market Overview
1.1 Age Related Macular Degeneration Drug Product Introduction
1.2 Global Age Related Macular Degeneration Drug Market Size Forecast
1.2.1 Global Age Related Macular Degeneration Drug Sales Value (2020-2031)
1.2.2 Global Age Related Macular Degeneration Drug Sales Volume (2020-2031)
1.2.3 Global Age Related Macular Degeneration Drug Sales Price (2020-2031)
1.3 Age Related Macular Degeneration Drug Market Trends & Drivers
1.3.1 Age Related Macular Degeneration Drug Industry Trends
1.3.2 Age Related Macular Degeneration Drug Market Drivers & Opportunity
1.3.3 Age Related Macular Degeneration Drug Market Challenges
1.3.4 Age Related Macular Degeneration Drug Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Age Related Macular Degeneration Drug Players Revenue Ranking (2024)
2.2 Global Age Related Macular Degeneration Drug Revenue by Company (2020-2025)
2.3 Global Age Related Macular Degeneration Drug Players Sales Volume Ranking (2024)
2.4 Global Age Related Macular Degeneration Drug Sales Volume by Company Players (2020-2025)
2.5 Global Age Related Macular Degeneration Drug Average Price by Company (2020-2025)
2.6 Key Manufacturers Age Related Macular Degeneration Drug Manufacturing Base and Headquarters
2.7 Key Manufacturers Age Related Macular Degeneration Drug Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Age Related Macular Degeneration Drug
2.9 Age Related Macular Degeneration Drug Market Competitive Analysis
2.9.1 Age Related Macular Degeneration Drug Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Age Related Macular Degeneration Drug Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age Related Macular Degeneration Drug as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Lucentis
3.1.2 Eylea
3.1.3 Avastin
3.1.4 Others
3.2 Global Age Related Macular Degeneration Drug Sales Value by Type
3.2.1 Global Age Related Macular Degeneration Drug Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Age Related Macular Degeneration Drug Sales Value, by Type (2020-2031)
3.2.3 Global Age Related Macular Degeneration Drug Sales Value, by Type (%) (2020-2031)
3.3 Global Age Related Macular Degeneration Drug Sales Volume by Type
3.3.1 Global Age Related Macular Degeneration Drug Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Age Related Macular Degeneration Drug Sales Volume, by Type (2020-2031)
3.3.3 Global Age Related Macular Degeneration Drug Sales Volume, by Type (%) (2020-2031)
3.4 Global Age Related Macular Degeneration Drug Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Others
4.2 Global Age Related Macular Degeneration Drug Sales Value by Application
4.2.1 Global Age Related Macular Degeneration Drug Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Age Related Macular Degeneration Drug Sales Value, by Application (2020-2031)
4.2.3 Global Age Related Macular Degeneration Drug Sales Value, by Application (%) (2020-2031)
4.3 Global Age Related Macular Degeneration Drug Sales Volume by Application
4.3.1 Global Age Related Macular Degeneration Drug Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Age Related Macular Degeneration Drug Sales Volume, by Application (2020-2031)
4.3.3 Global Age Related Macular Degeneration Drug Sales Volume, by Application (%) (2020-2031)
4.4 Global Age Related Macular Degeneration Drug Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Age Related Macular Degeneration Drug Sales Value by Region
5.1.1 Global Age Related Macular Degeneration Drug Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Age Related Macular Degeneration Drug Sales Value by Region (2020-2025)
5.1.3 Global Age Related Macular Degeneration Drug Sales Value by Region (2026-2031)
5.1.4 Global Age Related Macular Degeneration Drug Sales Value by Region (%), (2020-2031)
5.2 Global Age Related Macular Degeneration Drug Sales Volume by Region
5.2.1 Global Age Related Macular Degeneration Drug Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Age Related Macular Degeneration Drug Sales Volume by Region (2020-2025)
5.2.3 Global Age Related Macular Degeneration Drug Sales Volume by Region (2026-2031)
5.2.4 Global Age Related Macular Degeneration Drug Sales Volume by Region (%), (2020-2031)
5.3 Global Age Related Macular Degeneration Drug Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Age Related Macular Degeneration Drug Sales Value, 2020-2031
5.4.2 North America Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Age Related Macular Degeneration Drug Sales Value, 2020-2031
5.5.2 Europe Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Age Related Macular Degeneration Drug Sales Value, 2020-2031
5.6.2 Asia Pacific Age Related Macular Degeneration Drug Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Age Related Macular Degeneration Drug Sales Value, 2020-2031
5.7.2 South America Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Age Related Macular Degeneration Drug Sales Value, 2020-2031
5.8.2 Middle East & Africa Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Age Related Macular Degeneration Drug Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Age Related Macular Degeneration Drug Sales Value
6.2.1 Key Countries/Regions Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.2.2 Key Countries/Regions Age Related Macular Degeneration Drug Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.3.2 United States Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.4.2 Europe Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.5.2 China Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.5.3 China Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.6.2 Japan Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.7.2 South Korea Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.8.2 Southeast Asia Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Age Related Macular Degeneration Drug Sales Value, 2020-2031
6.9.2 India Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
6.9.3 India Age Related Macular Degeneration Drug Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Regeneron Pharmaceuticals
7.1.1 Regeneron Pharmaceuticals Company Information
7.1.2 Regeneron Pharmaceuticals Introduction and Business Overview
7.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Offerings
7.1.5 Regeneron Pharmaceuticals Recent Development
7.2 Bayer HealthCare
7.2.1 Bayer HealthCare Company Information
7.2.2 Bayer HealthCare Introduction and Business Overview
7.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Offerings
7.2.5 Bayer HealthCare Recent Development
7.3 Novartis
7.3.1 Novartis Company Information
7.3.2 Novartis Introduction and Business Overview
7.3.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Novartis Age Related Macular Degeneration Drug Product Offerings
7.3.5 Novartis Recent Development
7.4 Roche
7.4.1 Roche Company Information
7.4.2 Roche Introduction and Business Overview
7.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Roche Age Related Macular Degeneration Drug Product Offerings
7.4.5 Roche Recent Development
7.5 Kanghong Pharma
7.5.1 Kanghong Pharma Company Information
7.5.2 Kanghong Pharma Introduction and Business Overview
7.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Offerings
7.5.5 Kanghong Pharma Recent Development
8 Industry Chain Analysis
8.1 Age Related Macular Degeneration Drug Industrial Chain
8.2 Age Related Macular Degeneration Drug Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Age Related Macular Degeneration Drug Sales Model
8.5.2 Sales Channel
8.5.3 Age Related Macular Degeneration Drug Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma
List of Tables
 Table 1. Age Related Macular Degeneration Drug Market Trends
 Table 2. Age Related Macular Degeneration Drug Market Drivers & Opportunity
 Table 3. Age Related Macular Degeneration Drug Market Challenges
 Table 4. Age Related Macular Degeneration Drug Market Restraints
 Table 5. Global Age Related Macular Degeneration Drug Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Age Related Macular Degeneration Drug Revenue Market Share by Company (2020-2025)
 Table 7. Global Age Related Macular Degeneration Drug Sales Volume by Company (2020-2025) & (K Units)
 Table 8. Global Age Related Macular Degeneration Drug Sales Volume Market Share by Company (2020-2025)
 Table 9. Global Market Age Related Macular Degeneration Drug Price by Company (2020-2025) & (USD/Unit)
 Table 10. Key Manufacturers Age Related Macular Degeneration Drug Manufacturing Base and Headquarters
 Table 11. Key Manufacturers Age Related Macular Degeneration Drug Product Type
 Table 12. Key Manufacturers Time to Begin Mass Production of Age Related Macular Degeneration Drug
 Table 13. Global Age Related Macular Degeneration Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age Related Macular Degeneration Drug as of 2024)
 Table 15. Mergers & Acquisitions, Expansion Plans
 Table 16. Global Age Related Macular Degeneration Drug Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 17. Global Age Related Macular Degeneration Drug Sales Value by Type (2020-2025) & (US$ Million)
 Table 18. Global Age Related Macular Degeneration Drug Sales Value by Type (2026-2031) & (US$ Million)
 Table 19. Global Age Related Macular Degeneration Drug Sales Market Share in Value by Type (2020-2025)
 Table 20. Global Age Related Macular Degeneration Drug Sales Market Share in Value by Type (2026-2031)
 Table 21. Global Age Related Macular Degeneration Drug Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
 Table 22. Global Age Related Macular Degeneration Drug Sales Volume by Type (2020-2025) & (K Units)
 Table 23. Global Age Related Macular Degeneration Drug Sales Volume by Type (2026-2031) & (K Units)
 Table 24. Global Age Related Macular Degeneration Drug Sales Market Share in Volume by Type (2020-2025)
 Table 25. Global Age Related Macular Degeneration Drug Sales Market Share in Volume by Type (2026-2031)
 Table 26. Global Age Related Macular Degeneration Drug Price by Type (2020-2025) & (USD/Unit)
 Table 27. Global Age Related Macular Degeneration Drug Price by Type (2026-2031) & (USD/Unit)
 Table 28. Global Age Related Macular Degeneration Drug Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 29. Global Age Related Macular Degeneration Drug Sales Value by Application (2020-2025) & (US$ Million)
 Table 30. Global Age Related Macular Degeneration Drug Sales Value by Application (2026-2031) & (US$ Million)
 Table 31. Global Age Related Macular Degeneration Drug Sales Market Share in Value by Application (2020-2025)
 Table 32. Global Age Related Macular Degeneration Drug Sales Market Share in Value by Application (2026-2031)
 Table 33. Global Age Related Macular Degeneration Drug Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
 Table 34. Global Age Related Macular Degeneration Drug Sales Volume by Application (2020-2025) & (K Units)
 Table 35. Global Age Related Macular Degeneration Drug Sales Volume by Application (2026-2031) & (K Units)
 Table 36. Global Age Related Macular Degeneration Drug Sales Market Share in Volume by Application (2020-2025)
 Table 37. Global Age Related Macular Degeneration Drug Sales Market Share in Volume by Application (2026-2031)
 Table 38. Global Age Related Macular Degeneration Drug Price by Application (2020-2025) & (USD/Unit)
 Table 39. Global Age Related Macular Degeneration Drug Price by Application (2026-2031) & (USD/Unit)
 Table 40. Global Age Related Macular Degeneration Drug Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 41. Global Age Related Macular Degeneration Drug Sales Value by Region (2020-2025) & (US$ Million)
 Table 42. Global Age Related Macular Degeneration Drug Sales Value by Region (2026-2031) & (US$ Million)
 Table 43. Global Age Related Macular Degeneration Drug Sales Value by Region (2020-2025) & (%)
 Table 44. Global Age Related Macular Degeneration Drug Sales Value by Region (2026-2031) & (%)
 Table 45. Global Age Related Macular Degeneration Drug Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
 Table 46. Global Age Related Macular Degeneration Drug Sales Volume by Region (2020-2025) & (K Units)
 Table 47. Global Age Related Macular Degeneration Drug Sales Volume by Region (2026-2031) & (K Units)
 Table 48. Global Age Related Macular Degeneration Drug Sales Volume by Region (2020-2025) & (%)
 Table 49. Global Age Related Macular Degeneration Drug Sales Volume by Region (2026-2031) & (%)
 Table 50. Global Age Related Macular Degeneration Drug Average Price by Region (2020-2025) & (USD/Unit)
 Table 51. Global Age Related Macular Degeneration Drug Average Price by Region (2026-2031) & (USD/Unit)
 Table 52. Key Countries/Regions Age Related Macular Degeneration Drug Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 53. Key Countries/Regions Age Related Macular Degeneration Drug Sales Value, (2020-2025) & (US$ Million)
 Table 54. Key Countries/Regions Age Related Macular Degeneration Drug Sales Value, (2026-2031) & (US$ Million)
 Table 55. Key Countries/Regions Age Related Macular Degeneration Drug Sales Volume, (2020-2025) & (K Units)
 Table 56. Key Countries/Regions Age Related Macular Degeneration Drug Sales Volume, (2026-2031) & (K Units)
 Table 57. Regeneron Pharmaceuticals Company Information
 Table 58. Regeneron Pharmaceuticals Introduction and Business Overview
 Table 59. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 60. Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Offerings
 Table 61. Regeneron Pharmaceuticals Recent Development
 Table 62. Bayer HealthCare Company Information
 Table 63. Bayer HealthCare Introduction and Business Overview
 Table 64. Bayer HealthCare Age Related Macular Degeneration Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 65. Bayer HealthCare Age Related Macular Degeneration Drug Product Offerings
 Table 66. Bayer HealthCare Recent Development
 Table 67. Novartis Company Information
 Table 68. Novartis Introduction and Business Overview
 Table 69. Novartis Age Related Macular Degeneration Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 70. Novartis Age Related Macular Degeneration Drug Product Offerings
 Table 71. Novartis Recent Development
 Table 72. Roche Company Information
 Table 73. Roche Introduction and Business Overview
 Table 74. Roche Age Related Macular Degeneration Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 75. Roche Age Related Macular Degeneration Drug Product Offerings
 Table 76. Roche Recent Development
 Table 77. Kanghong Pharma Company Information
 Table 78. Kanghong Pharma Introduction and Business Overview
 Table 79. Kanghong Pharma Age Related Macular Degeneration Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 80. Kanghong Pharma Age Related Macular Degeneration Drug Product Offerings
 Table 81. Kanghong Pharma Recent Development
 Table 82. Key Raw Materials Lists
 Table 83. Raw Materials Key Suppliers Lists
 Table 84. Age Related Macular Degeneration Drug Downstream Customers
 Table 85. Age Related Macular Degeneration Drug Distributors List
 Table 86. Research Programs/Design for This Report
 Table 87. Key Data Information from Secondary Sources
 Table 88. Key Data Information from Primary Sources


List of Figures
 Figure 1. Age Related Macular Degeneration Drug Product Picture
 Figure 2. Global Age Related Macular Degeneration Drug Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Age Related Macular Degeneration Drug Sales Value (2020-2031) & (US$ Million)
 Figure 4. Global Age Related Macular Degeneration Drug Sales Volume (2020-2031) & (K Units)
 Figure 5. Global Age Related Macular Degeneration Drug Sales Price (2020-2031) & (USD/Unit)
 Figure 6. Age Related Macular Degeneration Drug Report Years Considered
 Figure 7. Global Age Related Macular Degeneration Drug Players Revenue Ranking (2024) & (US$ Million)
 Figure 8. Global Age Related Macular Degeneration Drug Players Sales Volume Ranking (2024) & (K Units)
 Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Age Related Macular Degeneration Drug Revenue in 2024
 Figure 10. Age Related Macular Degeneration Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 11. Lucentis Picture
 Figure 12. Eylea Picture
 Figure 13. Avastin Picture
 Figure 14. Others Picture
 Figure 15. Global Age Related Macular Degeneration Drug Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 16. Global Age Related Macular Degeneration Drug Sales Value Market Share by Type, 2024 & 2031
 Figure 17. Global Age Related Macular Degeneration Drug Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
 Figure 18. Global Age Related Macular Degeneration Drug Sales Volume Market Share by Type, 2024 & 2031
 Figure 19. Global Age Related Macular Degeneration Drug Price by Type (2020-2031) & (USD/Unit)
 Figure 20. Product Picture of Hospitals
 Figure 21. Product Picture of Clinics
 Figure 22. Product Picture of Others
 Figure 23. Global Age Related Macular Degeneration Drug Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 24. Global Age Related Macular Degeneration Drug Sales Value Market Share by Application, 2024 & 2031
 Figure 25. Global Age Related Macular Degeneration Drug Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
 Figure 26. Global Age Related Macular Degeneration Drug Sales Volume Market Share by Application, 2024 & 2031
 Figure 27. Global Age Related Macular Degeneration Drug Price by Application (2020-2031) & (USD/Unit)
 Figure 28. North America Age Related Macular Degeneration Drug Sales Value (2020-2031) & (US$ Million)
 Figure 29. North America Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
 Figure 30. Europe Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 31. Europe Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
 Figure 32. Asia Pacific Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Age Related Macular Degeneration Drug Sales Value by Region (%), 2024 VS 2031
 Figure 34. South America Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 35. South America Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
 Figure 36. Middle East & Africa Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 37. Middle East & Africa Age Related Macular Degeneration Drug Sales Value by Country (%), 2024 VS 2031
 Figure 38. Key Countries/Regions Age Related Macular Degeneration Drug Sales Value (%), (2020-2031)
 Figure 39. Key Countries/Regions Age Related Macular Degeneration Drug Sales Volume (%), (2020-2031)
 Figure 40. United States Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 41. United States Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 42. United States Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 43. Europe Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 44. Europe Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 45. Europe Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 46. China Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 47. China Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 48. China Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 49. Japan Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 50. Japan Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 51. Japan Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 52. South Korea Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 53. South Korea Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 54. South Korea Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 55. Southeast Asia Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 56. Southeast Asia Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 57. Southeast Asia Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 58. India Age Related Macular Degeneration Drug Sales Value, (2020-2031) & (US$ Million)
 Figure 59. India Age Related Macular Degeneration Drug Sales Value by Type (%), 2024 VS 2031
 Figure 60. India Age Related Macular Degeneration Drug Sales Value by Application (%), 2024 VS 2031
 Figure 61. Age Related Macular Degeneration Drug Industrial Chain
 Figure 62. Age Related Macular Degeneration Drug Manufacturing Cost Structure
 Figure 63. Channels of Distribution (Direct Sales, and Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Age Related Macular Degeneration Treatment Market Insights Forecast to 2030
Age relatedMacularDegeneration ARMD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Age Related Macular Degeneration AMD Therapeutics Market Insights Forecast to 2030
Global Age related Macular Degeneration Drugs Market Research Report 2025
Global Macular Degeneration Treatment Market Research Report 2024
Global Age Related Macular Degeneration AMD Treatment Drugs Market Research Report 2024
Global Ophthalmology for Age related Macular Degeneration Diseases Market Research Report 2024
Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2024
Global Age Related Macular Degeneration AMD AI Screening System Market Research Report 2024
Age related Macular Degeneration Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Wet Age Related Macular Degeneration Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Dry Age Related Macular Degeneration Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Ophthalmology Disorders Drug Market Insights Forecast to 2030
Global Macular Edema and Macular Degeneration Market Research Report 2025
Geographic Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Wet Macular Degeneration Market Research Report 2024
Global Geographic Atrophy Market Research Report 2025
Global Retinal Disorders Treatment Market Research Report 2024
Global Geographic Atrophy Drugs Market Research Report 2024
Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions